Amgen's Repatha Contract With Harvard Pilgrim Includes A Full Refund
Executive Summary
Harvard Pilgrim Chief Medical Officer Michael Sherman said the full warranty behind the agreement is the right kind of deal to balance access and cost.
You may also be interested in...
Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal
Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
The latest drug development news and highlights from our US FDA Performance Tracker.
The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics
Using a higher event rate typical of real-world, high-risk CV patients, Amgen asserts Repatha is cost effective at $9,669, the going discounted rate in the market. But criticism over the PCSK9 inhibitors' cost-effectiveness continues.